Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-21 EDT			5-day change	1st Jan Change
1.35 ^USD	+3.85%		-0.74%	-48.86%

06-07	Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee	CI
05-09	Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee

June 07, 2024 at 04:00 pm

On June 5, 2024, Michael J. Fox was appointed to the board of directors and the Compensation Committee of the Board of Cue Biopharma, Inc., following the recommendation of the Corporate Governance and Nominating Committee of the Board.

Latest news about Cue Biopharma, Inc.

Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee	06-07	CI
Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024	04-08
North American Morning Briefing : Inflation Data, -2-	04-08	DJ
Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
North American Morning Briefing : Tech in Focus on -2-	03-25	DJ
North American Morning Briefing : Investors -2-	03-18	DJ
Jefferies Starts Cue Biopharma With Buy Rating	03-13	MT
Transcript : Cue Biopharma, Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
Piper Sandler Adjusts Price Target on Cue Biopharma to $8 From $7, Maintains Overweight Rating	11-06	MT
Cue Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03	CI
Cue Biopharma Reports Prolonged Survival in Phase 1 Trials of CUE-101; Shares Climb	11-03	MT
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023	11-03	CI
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?	23-09-26	CI
Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023	23-09-14	CI
Transcript : Cue Biopharma, Inc., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
Cue Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000 Index	23-06-23	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000E Growth Index	23-06-23	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000E Index	23-06-23	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell Small Cap Completeness Index	23-06-23	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2000 Growth Index	23-06-23	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2500 Index	23-06-23	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2000 Index	23-06-23	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000 Growth Index	23-06-23	CI

Chart Cue Biopharma, Inc.

Duration

Period

More charts

Company Profile

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.

Sector

Biotechnology & Medical Research

Calendar

11:00am - Oppenheimer Novel Targets in Immunology Summit

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Cue Biopharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.35 USD

Average target price

9.4 USD

Spread / Average Target

+596.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CUE BIOPHARMA, INC.	-48.86%	65.67M
VERTEX PHARMACEUTICALS INCORPORATED	+15.19%	121B
REGENERON PHARMACEUTICALS, INC.	+19.91%	114B
BIONTECH SE	-19.80%	20.43B
GENMAB A/S	-15.92%	16.55B
BEIGENE, LTD.	-13.45%	16.45B
WUXI APPTEC CO., LTD.	-44.35%	15.59B
SAREPTA THERAPEUTICS, INC.	+66.67%	15.19B
NEUROCRINE BIOSCIENCES, INC.	+2.13%	13.54B
INSMED INCORPORATED	+119.39%	10.96B

Bio Therapeutic Drugs